BusinessAnthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be Included in the European Cystic Fibrosis Clinical Trial NetworkBy Nasdaq OMXAug 14, 2017, 12:30 PM UTC
BusinessAnthera Pharmaceuticals Provides Business Update and Reports 2017 Second Quarter Financial ResultsBy Nasdaq OMXAug 9, 2017, 12:30 PM UTC
BusinessAnthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study of Sollpura will be included in the Cystic Fibrosis Foundation Therapeutics Development NetworkBy Nasdaq OMXJul 10, 2017, 12:30 PM UTC
BusinessAnthera Announces Expansion of Screening in European Sites in Phase 3 RESULT Clinical Study of SollpuraBy Nasdaq OMXJul 6, 2017, 12:30 PM UTC
BusinessProQR to Participate in a Cystic Fibrosis Panel Discussion during the JMP Securities Life Science ConferenceBy Nasdaq OMXJun 13, 2017, 11:00 AM UTC
BusinessProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EUBy Nasdaq OMXApr 3, 2017, 11:02 AM UTC
BusinessProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EUBy Nasdaq OMXApr 3, 2017, 11:02 AM UTC
BusinessProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EUBy Nasdaq OMXApr 3, 2017, 11:02 AM UTC
